Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11548
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTurner, Natalieen
dc.contributor.authorStewart, Josephineen
dc.contributor.authorBarnett, Francesen
dc.contributor.authorWhite, Shane Cen
dc.date.accessioned2015-05-16T01:09:44Z
dc.date.available2015-05-16T01:09:44Z
dc.date.issued2012-05-02en
dc.identifier.citationAsia-pacific Journal of Clinical Oncology 2012; 8(3): e9-e11en
dc.identifier.govdoc22897880en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11548en
dc.description.abstractCarboplatin is a platinum analogue, widely used in the treatment of numerous cancer types including lung, genitourinary and ovarian cancers. It is also used in the adjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer, where a non-anthracycline regimen is preferred. It is considered generally to be less toxic though potentially less efficacious than cisplatin, another platinum compound. Cisplatin is well recognized as causing hyponatremia, through the mechanism of renal salt wasting. Conversely, carboplatin has only rarely been associated with hyponatremia. We report here a case of severe hyponatremia occurring 6 days after adjuvant treatment with a carboplatin-containing chemotherapy regimen for early stage breast cancer. The mechanism of hyponatremia was consistent with the syndrome of inappropriate anti-diuretic hormone secretion based on biochemical and clinical findings, and response to fluid restriction. With no previously reported cases of docetaxel-associated or trastuzumab-associated hyponatremia, the causative agent was considered to be carboplatin. Additionally there was no recurrence of hyponatremia on recommencement of docetaxel and trastuzumab therapy. Hyponatremia secondary to carboplatin has been rarely reported in the literature, with only three previously reported cases. Although it is rare, oncologists should be aware of the potential for carboplatin to cause hyponatremia and the need to monitor electrolytes throughout therapy.en
dc.language.isoenen
dc.subject.otherAntibodies, Monoclonal, Humanized.administration & dosage.adverse effectsen
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic useen
dc.subject.otherBreast Neoplasms.blood.drug therapy.enzymologyen
dc.subject.otherCarboplatin.administration & dosage.adverse effectsen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherHyponatremia.chemically induced.enzymologyen
dc.subject.otherInappropriate ADH Syndrome.chemically induced.enzymologyen
dc.subject.otherMiddle Ageden
dc.subject.otherReceptor, ErbB-2.metabolismen
dc.subject.otherTaxoids.administration & dosage.adverse effectsen
dc.titleSyndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia-Pacific journal of clinical oncologyen
dc.identifier.affiliationThe Northern Hospital Austin Hospital, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/j.1743-7563.2012.01526.xen
dc.description.pagese9-e11en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22897880en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.